KR20150027752A - 인간화된 il-7 설치류 - Google Patents
인간화된 il-7 설치류 Download PDFInfo
- Publication number
- KR20150027752A KR20150027752A KR1020147035047A KR20147035047A KR20150027752A KR 20150027752 A KR20150027752 A KR 20150027752A KR 1020147035047 A KR1020147035047 A KR 1020147035047A KR 20147035047 A KR20147035047 A KR 20147035047A KR 20150027752 A KR20150027752 A KR 20150027752A
- Authority
- KR
- South Korea
- Prior art keywords
- human
- humanized
- exon
- rodent
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000283984 Rodentia Species 0.000 title claims abstract description 141
- 241000282414 Homo sapiens Species 0.000 claims abstract description 244
- 108010002586 Interleukin-7 Proteins 0.000 claims abstract description 218
- 102000000704 Interleukin-7 Human genes 0.000 claims abstract description 181
- 210000004027 cell Anatomy 0.000 claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 230000001105 regulatory effect Effects 0.000 claims abstract description 23
- 210000004602 germ cell Anatomy 0.000 claims abstract description 11
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims description 121
- 102000052622 human IL7 Human genes 0.000 claims description 121
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 95
- 241000699670 Mus sp. Species 0.000 claims description 73
- 241000700159 Rattus Species 0.000 claims description 33
- 108700024394 Exon Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 21
- 238000011144 upstream manufacturing Methods 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 241000699800 Cricetinae Species 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 210000001541 thymus gland Anatomy 0.000 claims description 6
- 108700019146 Transgenes Proteins 0.000 claims description 5
- 210000002980 germ line cell Anatomy 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 108091023045 Untranslated Region Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 101001043808 Mus musculus Interleukin-7 Proteins 0.000 abstract description 26
- 229940100994 interleukin-7 Drugs 0.000 abstract description 9
- 210000002257 embryonic structure Anatomy 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 73
- 108020004414 DNA Proteins 0.000 description 24
- 238000011830 transgenic mouse model Methods 0.000 description 23
- 101100508566 Homo sapiens IL7 gene Proteins 0.000 description 22
- 241000699660 Mus musculus Species 0.000 description 22
- 239000012634 fragment Substances 0.000 description 17
- 230000002093 peripheral effect Effects 0.000 description 15
- 241001529936 Murinae Species 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 102000015696 Interleukins Human genes 0.000 description 9
- 108010063738 Interleukins Proteins 0.000 description 9
- 108091036066 Three prime untranslated region Proteins 0.000 description 8
- 206010009887 colitis Diseases 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 5
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003519 mature b lymphocyte Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 101100508567 Mus musculus Il7 gene Proteins 0.000 description 4
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 108020005065 3' Flanking Region Proteins 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 241000398750 Muroidea Species 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 208000019420 lymphoid neoplasm Diseases 0.000 description 2
- 230000001589 lymphoproliferative effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011714 129 mouse Methods 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- 241001529504 Brachytarsomys albicauda Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 241000398949 Calomyscidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 241001095404 Dipodoidea Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 241000398990 Nesomyidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000393460 Peromyscus nasutus Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001338313 Platacanthomyidae Species 0.000 description 1
- 102000000434 Pre-B Cell Receptors Human genes 0.000 description 1
- 108010016231 Pre-B Cell Receptors Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000398956 Spalacidae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241001105470 Valenzuela Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 210000003595 dermal dendritic cell Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000009675 homeostatic proliferation Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Catching Or Destruction (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660976P | 2012-06-18 | 2012-06-18 | |
| US61/660,976 | 2012-06-18 | ||
| US201261740074P | 2012-12-20 | 2012-12-20 | |
| US61/740,074 | 2012-12-20 | ||
| US13/795,765 | 2013-03-12 | ||
| US13/795,765 US8962913B2 (en) | 2012-06-18 | 2013-03-12 | Humanized IL-7 rodents |
| PCT/US2013/045788 WO2013192030A1 (en) | 2012-06-18 | 2013-06-14 | Humanized il-7 rodents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150027752A true KR20150027752A (ko) | 2015-03-12 |
Family
ID=49757275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147035047A Ceased KR20150027752A (ko) | 2012-06-18 | 2013-06-14 | 인간화된 il-7 설치류 |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US8962913B2 (enExample) |
| EP (2) | EP2861063A1 (enExample) |
| JP (1) | JP6174134B2 (enExample) |
| KR (1) | KR20150027752A (enExample) |
| CN (2) | CN104378976B (enExample) |
| AU (1) | AU2013277457B2 (enExample) |
| BR (1) | BR112014029892A2 (enExample) |
| CA (1) | CA2873134A1 (enExample) |
| CY (1) | CY1119071T1 (enExample) |
| DK (1) | DK2859793T3 (enExample) |
| ES (1) | ES2626965T3 (enExample) |
| HK (1) | HK1203761A1 (enExample) |
| HR (1) | HRP20170974T1 (enExample) |
| HU (1) | HUE034592T2 (enExample) |
| IL (3) | IL235773B (enExample) |
| IN (1) | IN2014DN10189A (enExample) |
| LT (1) | LT2859793T (enExample) |
| MX (1) | MX363540B (enExample) |
| NZ (1) | NZ702943A (enExample) |
| PL (1) | PL2859793T3 (enExample) |
| PT (1) | PT2859793T (enExample) |
| RS (1) | RS56039B1 (enExample) |
| RU (1) | RU2654565C2 (enExample) |
| SG (3) | SG10201609576YA (enExample) |
| SI (1) | SI2859793T1 (enExample) |
| SM (1) | SMT201700313T1 (enExample) |
| WO (1) | WO2013192030A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210108828A (ko) | 2020-02-26 | 2021-09-03 | 차의과학대학교 산학협력단 | 동물 면역계의 인간화 활성을 촉진하는 방법 |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3241435T3 (da) * | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| AU2012311286B2 (en) | 2011-09-19 | 2018-07-26 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| CA2866363C (en) * | 2012-03-05 | 2019-08-27 | Samsung Electronics Co., Ltd. | Harq-ack signal transmission in response to detection of control channel type in case of multiple control channel types |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| US8962913B2 (en) * | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| HRP20231121T1 (hr) | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| JP6492095B2 (ja) | 2013-10-15 | 2019-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒト化ｉｌ−１５動物 |
| US20150143559A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
| ES2950399T3 (es) * | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
| WO2017136712A1 (en) | 2016-02-04 | 2017-08-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered angptl8 gene |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| GB201710984D0 (en) | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| CA3098040A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| WO2020147829A1 (zh) * | 2019-01-17 | 2020-07-23 | 北京百奥赛图基因生物技术有限公司 | 人源化转基因动物 |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化凝固因子１２遺伝子座を含む非ヒト動物 |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| US20220312749A1 (en) * | 2019-08-09 | 2022-10-06 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
| WO2021154791A1 (en) * | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| CN111926039B (zh) * | 2020-09-23 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | Il-13基因人源化的非人动物的构建方法和应用 |
| JP2024500153A (ja) * | 2020-12-21 | 2024-01-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｓｌｐ遺伝子、ヒト化ｔｓｌｐ受容体遺伝子、及び／又はヒト化ｉｌ７ｒａ遺伝子を有する非ヒト動物 |
| CN114835798B (zh) * | 2021-05-28 | 2024-02-23 | 百奥赛图(北京)医药科技股份有限公司 | Cd36基因人源化非人动物的构建方法及应用 |
| US20230417899A1 (en) * | 2022-06-27 | 2023-12-28 | Oshkosh Corporation | Position tracking for a lift device |
| AU2023338373A1 (en) * | 2022-09-08 | 2025-04-03 | The Jackson Laboratory | Humanized immunodeficient mouse models |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA887773B (en) * | 1987-10-26 | 1989-07-26 | Immunex Corp | Interleukin-7 |
| EP1209968A1 (en) | 1999-08-31 | 2002-06-05 | Genencor International, Inc. | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
| CN101302517B (zh) * | 2008-02-03 | 2010-11-03 | 中国科学院广州生物医药与健康研究院 | 人白细胞介素7在真核宿主中表达的方法 |
| EP4502152A3 (en) * | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| SI2818478T1 (sl) | 2011-10-28 | 2017-07-31 | Regeneron Pharmaceuticals, Inc. | Humanizirani il-6 in receptor il-6 |
| US8962913B2 (en) * | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
-
2013
- 2013-03-12 US US13/795,765 patent/US8962913B2/en not_active Expired - Fee Related
- 2013-06-14 AU AU2013277457A patent/AU2013277457B2/en not_active Ceased
- 2013-06-14 CN CN201380031333.4A patent/CN104378976B/zh not_active Expired - Fee Related
- 2013-06-14 RS RS20170543A patent/RS56039B1/sr unknown
- 2013-06-14 SI SI201330664A patent/SI2859793T1/sl unknown
- 2013-06-14 HK HK15104315.3A patent/HK1203761A1/xx unknown
- 2013-06-14 LT LTEP14195502.1T patent/LT2859793T/lt unknown
- 2013-06-14 PT PT141955021T patent/PT2859793T/pt unknown
- 2013-06-14 SG SG10201609576YA patent/SG10201609576YA/en unknown
- 2013-06-14 ES ES14195502.1T patent/ES2626965T3/es active Active
- 2013-06-14 KR KR1020147035047A patent/KR20150027752A/ko not_active Ceased
- 2013-06-14 PL PL14195502T patent/PL2859793T3/pl unknown
- 2013-06-14 JP JP2015517447A patent/JP6174134B2/ja not_active Expired - Fee Related
- 2013-06-14 SG SG11201407370QA patent/SG11201407370QA/en unknown
- 2013-06-14 CN CN201610168011.XA patent/CN105779467A/zh active Pending
- 2013-06-14 DK DK14195502.1T patent/DK2859793T3/en active
- 2013-06-14 MX MX2014015679A patent/MX363540B/es unknown
- 2013-06-14 NZ NZ702943A patent/NZ702943A/en not_active IP Right Cessation
- 2013-06-14 WO PCT/US2013/045788 patent/WO2013192030A1/en not_active Ceased
- 2013-06-14 SG SG10201609569PA patent/SG10201609569PA/en unknown
- 2013-06-14 BR BR112014029892A patent/BR112014029892A2/pt not_active Application Discontinuation
- 2013-06-14 HU HUE14195502A patent/HUE034592T2/en unknown
- 2013-06-14 EP EP13739875.6A patent/EP2861063A1/en not_active Withdrawn
- 2013-06-14 RU RU2014148107A patent/RU2654565C2/ru not_active IP Right Cessation
- 2013-06-14 CA CA2873134A patent/CA2873134A1/en not_active Abandoned
- 2013-06-14 EP EP14195502.1A patent/EP2859793B1/en active Active
- 2013-06-14 SM SM20170313T patent/SMT201700313T1/it unknown
-
2014
- 2014-11-18 IL IL235773A patent/IL235773B/en active IP Right Grant
- 2014-11-24 US US14/551,538 patent/US9232776B2/en not_active Expired - Fee Related
- 2014-11-28 IN IN10189DEN2014 patent/IN2014DN10189A/en unknown
-
2015
- 2015-11-10 US US14/937,270 patent/US20160052986A1/en not_active Abandoned
-
2016
- 2016-11-21 US US15/357,021 patent/US9737059B2/en not_active Expired - Fee Related
-
2017
- 2017-05-31 CY CY20171100577T patent/CY1119071T1/el unknown
- 2017-06-27 HR HRP20170974TT patent/HRP20170974T1/hr unknown
- 2017-07-14 US US15/649,797 patent/US9974291B2/en not_active Expired - Fee Related
-
2018
- 2018-04-24 US US15/960,642 patent/US10314298B2/en not_active Expired - Fee Related
- 2018-06-25 IL IL260250A patent/IL260250B/en not_active IP Right Cessation
-
2019
- 2019-05-01 US US16/400,074 patent/US20190343093A1/en not_active Abandoned
- 2019-08-13 IL IL26867419A patent/IL268674A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210108828A (ko) | 2020-02-26 | 2021-09-03 | 차의과학대학교 산학협력단 | 동물 면역계의 인간화 활성을 촉진하는 방법 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013277457B2 (en) | Humanized IL-7 rodents | |
| KR102291355B1 (ko) | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 | |
| AU2015286663B2 (en) | Antisense oligonucleotides for the treatment of usher syndrome type 2 | |
| KR101778036B1 (ko) | 전립선암 마커로서의 포스포디에스테라제 4ｄ7 | |
| KR20210138587A (ko) | 개선된 면역요법을 위한 조합 유전자 표적 | |
| KR20230034198A (ko) | 종양 침윤 림프구의 활성화 및 확장 방법 | |
| AU2016325030A1 (en) | Novel biomarkers and methods of treating cancer | |
| AU2018364916B2 (en) | Therapeutic pharmaceutical composition for cancer including miRNA | |
| KR20220025806A (ko) | 핵산의 무작위 구성 표적화 통합 | |
| KR20230074214A (ko) | 지방간 질환의 치료 방법 | |
| AU2019339404B2 (en) | Complement factor h gene knockout rat as a model of C3 glomerulopathy | |
| KR102424119B1 (ko) | 저하된 상위 및 하위 운동 뉴런 기능 및 감각 지각을 나타내는 비-인간 동물 | |
| CN101151371B (zh) | 治疗中的逆转录转座子抑制 | |
| KR20080096495A (ko) | 소과 동물에서 배최장근 최대력, 근내 지방, 식용우소매유통 생산량 및 순 사료 섭취량으로부터 선택된 형질을평가하는 방법 | |
| US20160250182A1 (en) | Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk | |
| CN113473850A (zh) | 具有遗传修饰的钠通道的啮齿动物及其使用方法 | |
| CA2474759A1 (en) | Gene for peripheral arterial occlusive disease | |
| CN116802200A (zh) | 具有人源化tslp基因、人源化tslp受体基因和/或人源化il7ra基因的非人动物 | |
| CN114835798A (zh) | Cd36基因人源化非人动物的构建方法及应用 | |
| US20160184454A1 (en) | Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk | |
| CN108135151A (zh) | 前列腺癌的啮齿动物模型 | |
| CN113817770B (zh) | Cd73基因人源化的非人动物的构建方法及应用 | |
| RU2839460C1 (ru) | Лечение ожирения у субъектов молекулами вариантов нуклеиновых кислот, кодирующими рецептор кальцитонина (calcr) | |
| US20040238597A1 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
| EA048246B1 (ru) | Способ лечения жировой болезни печени |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20141212 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180516 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20191022 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20191230 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20191022 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |